This Indefinite Delivery Contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Dynport Vaccine Company LLC, a subsidiary of General Dynamics. The contract, valued at a ceiling of $346,610,277, is for Early Phase Clinical Trial Units (EPCTU) services to support Phase 0 through Phase II clinical trials of investigational products targeting infectious diseases. The contract has a period of performance through January 13, 2032 and does not utilize any set-asides. Dynport Vaccine Company LLC, with its Maryland-based facilities, provides a range of research, development, manufacturing, and testing services to support biopharmaceutical products.
The contract includes two delivery orders awarded to date. The first is a $2,265,501 cost-plus-fixed-fee order for EPCTU services, with a period of performance through January 31, 2025 and a subcontract to Altasciences Clinical Kansas Inc. The second is a $4.38 million cost-plus-fixed-fee order for clinical trial support services, with a period of performance from January 2022 through January 2032. This EPCTU IDIQ contract was originally solicited through a pre-solicitation notice seeking multiple awards to support Phase 0 through Phase II trials of investigational infectious disease products, with the potential for Phase III trials in urgent public health scenarios.
Generated 12/5/24, 9:05 AM